Showing posts with label breast cancer risk. Show all posts
Showing posts with label breast cancer risk. Show all posts
Thursday, April 12, 2012
Does Estrogen-Only HRT Decrease Breast Cancer Risk? Nationally Recognized Endocrinologist Dr. Marina Johnson Weighs In
Does Estrogen-Only HRT Decrease Breast Cancer Risk? Nationally Recognized Endocrinologist Dr. Marina Johnson Weighs In
"....So here's Dr. Johnson's take-home message: "You don't need to delay starting HRT if you choose natural estradiol and progesterone over synthetic estrogens and progestins. Don't endure symptoms like hot flashes, insomnia, anxiety, depression, sexual dysfunction, mental confusion, and weight gain. Start HRT within 10 years of menopause for the most protection against Heart Disease, Alzheimer's and Osteoporosis.
"Avoid the increased heart attacks and strokes seen in WHI by choosing topical estrogen in the form of patches, gels, creams and mists that are available at any drug store. Pharmaceutical natural hormones (also called bioidentical hormones) are superior to compounded bioidentical hormones because they are required to meet higher standards for quality control and efficacy."
Read more in Dr. Johnson's book, "Outliving Your Ovaries: An Endocrinologist Weighs The Risks And Rewards Of Treating Menopause With Hormone Replacement Therapy" (http://www.outlivingyourovaries.com) (Eyesong Publishing, February 2011), which is available in paperback, e-book and can be shipped internationally. Use coupon code BZCWJDM5 for $5 off of the retail price with purchase at http://www.buydrmarinajohnsonbook.com.
Dr. Marina Johnson, a pharmacist and UCLA/USC-trained physician, is board-certified in Endocrinology and Internal Medicine.
add your opinions
breast cancer risk
,
estrogen
Tuesday, January 24, 2012
Jan 2012 abstract: Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening
Blogger's Note: in this study longterm followup = 2 years
Abstract
There
are two mutations in BRCA1 and one in BRCA2, which are present in up to
2.5% of Jewish women. Population genetic testing
for Jewish women has been proposed; however, it is unclear
how this would impact the uptake of cancer prevention options and
psychosocial functioning in women with a positive result.
Two thousand and eighty unselected Jewish women were tested for
the Jewish BRCA mutations, and 1.1% were positive.
Cancer-related distress was measured before testing, and at 1 and
2 years
post-testing. Information on uptake of cancer risk reduction
options was collected at 2 years. Breast and ovarian cancer risks
were estimated using BRCAPRO. Within 2 years of receiving a
positive result, 11.1% of women had prophylactic mastectomy, and
89.5% had a prophylactic oophorectomy. The mean breast
cancer risk was estimated to be 37.2% at time of testing, compared
to 20.9% at 2 years post-testing. The mean ovarian cancer
risk was estimated to be 24.5% at time of testing, compared to 7.5%
at 2 years following testing. Distress decreased between 1
and 2 years for women with prophylactic mastectomy and oophorectomy
(P = 0.02), and for women with prophylactic oophorectomy only (P = 0.04)
but not for those with neither surgery. The majority of Jewish women
with a BRCA mutation identified through a population
screening elected prophylactic oophorectomy, but a few had a
prophylactic mastectomy. Uptake of either surgery resulted in
decreased distress. Provision of population BRCA testing
resulted in reduced risks of breast and ovarian cancers in women
with a mutation.
Keywords BRCA1 – BRCA2 – Breast cancer – Genetic testing – Jewish
add your opinions
BRCA
,
breast cancer risk
,
distress
,
Jewish
,
ovarian cancer risk
,
prophylactic surgery
Tuesday, September 14, 2010
Wednesday, August 11, 2010
AACR Hosts Cancer Disparities Conference in Miami, Fla. abstract online Sept
This year, the American Association for Cancer Research will host its third conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved at the Loews Miami Beach Hotel in Miami, Fla.
Findings presented at this year’s meeting will include:
• proven communication methods for reaching minority populations;
• strategies to increase enrollment in clinical trials;
• prognosis in lung cancer affected by race;
• breast cancer trends in Arab and Israeli Jewish women;
• the importance of social support and physical activity in survivors; and,
• socioeconomics and access to health care.
To help you plan your coverage of the conference, the program schedule is available online at
http://www.aacr.org/disparities2010
abstracts will be available on Sept. 22, 2010
add your opinions
aacr
,
access
,
Arab
,
breast cancer risk
,
clinical trials
,
conference
,
disparities
,
economics
,
ethnicity
,
Jewish
,
minorities
,
racial
,
social support
,
socioeconomics
Subscribe to:
Posts
(
Atom
)